Samantha Greene, President & Chief Executive Officer
Samantha Greene is a leader and entrepreneur with more than 20 years’ experience in the medical device and biotech arena, primarily in the cardiovascular space. She recently closed the Company’s Series B financing in the midst of the COVID-19 pandemic. The Company’s exit from stealth mode in 2015 was engineered and executed by Ms. Greene through a novel funding model. Prior to joining MVRx, Greene served in increasingly responsible leadership roles at Biosensors, Edwards and IsoStent and led 3 different first in the world clinical trials including the first consecutive patient trial in TAVR, the 1st randomized trial in DES and 1 month DAPT and conceived of and led the initiative that resulted in the first FDA single arm pivotal trial in DES. Ms. Greene has a BA in History from Union College.